(TLSI)

NGM – Real Time Price. Currency in USD

3.85

-0.07 (-1.79%)

At close: Mar 27, 2026, 4:00 PM EDT

3.78

-0.07 (-1.82%)

After-hours: Mar 27, 2026, 4:51 PM EDT

About the company

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff. The company was founded in 2009 and is headquartered in Westminster, Colorado.

Key Executives

Name	Position
Andrea Marasso	Vice President of Marketing
Dr. Bryan F. Cox Ph.D.	Chief of Research
Dr. Richard Marshall	Medical Director
Dr. Richard B. Marshak M.B.A., VMD	Chief Commercial Officer
Mr. David B. Patience	Chief Financial Officer
Ms. Jennifer L. Stevens J.D.	Chief Regulatory Officer
Ms. Jodi Devlin	Chief of Clinical Strategy & Operations
Ms. Mary T. Szela B.S.N., M.B.A.